www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Sinopharm unit inches toward vaccine breakthrough

By Liu Zhihua | China Daily | Updated: 2020-04-30 10:42
Share
Share - WeChat
A China National Biotech Group Co Ltd employee displays a COVID-19 inactive vaccine, which is under development and trials, at the company's research institute in Wuhan, capital of Hubei province, on April 10. [Photo/Xinhua]

State-owned CNBG teams up with partners to step up development of effective, lasting treatment for COVID-19

Chinese State-owned pharmaceutical giant Sinopharm Group has made substantial progress in developing vaccine candidates for the novel coronavirus that causes COVID-19.

China National Biotech Group Co Ltd, Sinopharm's vaccine and bioscience unit, announced on Monday that its second inactivated vaccine targeting the contagion won clinical trial approval from the National Medical Products Administration. The vaccine is codeveloped by a unit under CNBG-Beijing Institute of Biological Products Co Ltd-and the Chinese Center for Disease Control and Prevention.

On Friday, CNBG launched phase-2 human trials of its first inactivated vaccine, which is codeveloped by its unit, the Wuhan Institute of Biological Products, along with the Wuhan Institute of Virology under the Chinese Academy of Sciences.

Approved for clinical trials on April 12, the vaccine was the first inactivated vaccine worldwide to reach such a developed approval stage. The NMPA authorized its phase-1 and phase-2 human trials at the same time on that day through a fast-track channel based on solid results from preclinical trial studies.

"The world is racing to develop COVID-19 vaccines, yet it is not a competition between countries, but rather a race between humans and the virus," said Yang Xiaoming, president of CNBG.

Yang said it is quite encouraging to have developed inactivated vaccines against COVID-19.

Inactivated vaccines use nonliving viruses, bacteria or other pathogens that have lost disease-producing capacity to stimulate the immune system to develop an immune response.

Wang Junzhi, an academic at the Chinese Academy of Engineering, said China has laid a solid foundation to research inactivated vaccines in recent years, and inactivated vaccines have been widely used to fight hepatitis A, influenza, poliomyelitis, and hand, foot and mouth disease.

Yang added that China has distinctive advantages in developing vaccines against the disease thanks to the country's institutional features that can unite resources and efforts of different participants to concentrate on a specific program and target.

1 2 3 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 欧美一区二区三区不卡 | 成人免费看www网址入口 | 久久伊人热 | 91精品国产91久久久久久青草 | 欧美日韩大片 | 一本久 | 成年人在线免费 | 91精品国产薄丝高跟在线看 | 日韩久久综合 | 国产成人精品一区 | 国产精品视频久 | dvd8090cnm欧美大片 | 久久精品视频网 | 黄色一级片在线看 | 久久国产精品99久久久久久牛牛 | 欧美亚洲日本韩国一级毛片 | 国产深夜福利视频在线播放 | 日韩美女免费线视频 | 欧美在线一二三区 | 久久久久久久久一级毛片 | 在线成人天天鲁夜啪视频 | 国产精品久久久久久搜索 | 亚洲欧美一区二区三区孕妇 | 成人做爰视频www在线观看 | 99久久国产免费 - 99久久国产免费 | 一级毛片免费不卡在线视频 | 精品国产香蕉伊思人在线 | 精品国产免费一区二区三区 | 美女又爽又黄视频 | 人碰人碰人成人免费视频 | 欧美一级大尺度毛片 | 韩国一级淫片视频免费播放 | 国产视频合集 | 99久久精品国产国产毛片 | 国产综合亚洲专区在线 | 久草色视频 | 美女视频网站免费播放视 | 亚洲一区中文字幕在线 | 国产精品亚洲二线在线播放 | 国产男女爽爽爽爽爽免费视频 | 国产美女在线精品观看 |